NCT03631953View on ClinicalTrials.gov

Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

January 29, 2026

Study Completion Date

January 29, 2026

Conditions
Meningioma
Interventions
DRUG

Trametinib

Trametinib administered at a fixed dose (1.5 mg daily)

DRUG

Alpelisib

A panel of 3 doses of ALPELISIB could be tested

BIOLOGICAL

Blood sample

Therapeutic biomarkers

DEVICE

MRI

A MRI with contrast will be performed before treatment start. Assessment of tumor growth.

Trial Locations (1)

13354

RECRUITING

Assistance Publique Hôpitaux de Marseille, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER